{
    "title": "Change at the top for Biogen after Alzheimer's drug flops",
    "url": "https://www.dailymail.co.uk/wires/ap/article-10778313/Change-Biogen-struggles-Aduhelm.html",
    "date": "2022-05-03",
    "keywords": [
        "drug",
        "biogen",
        "company",
        "year",
        "aduhelm",
        "vounatsos",
        "ceo",
        "marketing",
        "share",
        "successor",
        "plan",
        "companys",
        "business",
        "cambridge",
        "market",
        "price",
        "decision",
        "inc",
        "tuesday",
        "month",
        "medicare",
        "quarter",
        "backlash",
        "architect",
        "strategy",
        "spending",
        "part",
        "dollar",
        "costsaving",
        "biotech",
        "announcement",
        "acknowledgement",
        "introduction",
        "evidence",
        "progression",
        "coverage",
        "tag",
        "benefit",
        "half",
        "mass",
        "launch",
        "michel",
        "setback",
        "health",
        "majority",
        "march",
        "inventory",
        "infrastructure",
        "street",
        "income",
        "application",
        "europe",
        "confirmatory",
        "trial",
        "revenue",
        "sclerosis",
        "competition",
        "specialty",
        "spinraza",
        "disorder",
        "guidance",
        "laststage",
        "fall",
        "pipeline",
        "depression",
        "schizophrenia",
        "departure",
        "capital",
        "analyst",
        "move",
        "reorganization",
        "term",
        "start"
    ],
    "category": [
        "wires",
        "ap"
    ]
}